Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | RXRB | P28702 | 2/20 | 0.32 |
| ▸ | RXRG | P48443 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17211805 | 0.80 | SIRT2 (0.30) | — | |
| SCHEMBL17211806 | 0.79 | PDE4D (0.31) | PDE4DKARS1 | |
| SCHEMBL17211819 | 0.79 | PDE4D (0.31) | PDE4DKARS1 | |
| SCHEMBL17211810 | 0.72 | MAOA (0.44) | — | |
| SCHEMBL17211800 | 0.71 | CYP2A6 (0.35) | — | |
| SCHEMBL17211816 | 0.69 | CYP26A1 (0.31) | — | |
| SCHEMBL17211813 | 0.65 | CYP26A1 (0.32) | — | |
| SCHEMBL17551902 | 0.62 | KDM1A (0.56) | KDM1ARXRARXRBRXRG | |
| SCHEMBL25369126 | 0.62 | RXRA (0.41) | KDM1ARXRARXRBRXRGPDE4D | |
| SCHEMBL23704441 | 0.61 | KDM1A (0.48) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | DGAT1, DGAT2, LCAT | KDM1A 3473/4885RXRA 827/4885RXRB 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.